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Abstract This article questions the scientific justification of
ingrained radiologic practices exemplified by size measure-
ments of childhood solid tumours. This is approached by a
critical review of staging systems from a selection of paediat-
ric oncological treatment protocols. Local staging remains
size-dependent for some tumour types. The consequent stage
assignment can significantly influence treatment intensity.
Still, the protocols tend not to give precise guidance on how
to perform scans and standardise measurements. Also, they do
not estimate or account for the inevitable variability in mea-
surements. Counts and measurements of lung nodules are,
within some tumour groups, used for diagnosis of metastatic
disease. There is, however, no evidence that nodule size is a
useful discriminator of benign and malignant lung nodules.
The efficacy of imaging depends chiefly on observations
being precise, accurate and valid for the desired diagnostic
purpose. Because measurements without estimates of their
errors are meaningless, studies of variability dependent on
tumour shape and location, imaging device and observer need
to be encouraged. Reproducible observations make good can-
didates for staging parameters if they have prognostic validity
and at the same time show little covariation with (thereby
adding new information to) the existing staging system. The
lack of scientific rigour has made the validity of size measure-
ment very difficult to assess. Action is needed, the most
important being radiologists’ active contribution in develop-
ment of oncological staging systems, attention to
standardisation, knowledge about errors in measurement and
protection against undue influence of such errors in the stag-
ing of the individual child.
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Introduction
Quantities give confidence, and perhaps consolation. As radi-
ologists we wish to categorise, score and measure. Describing
and reporting on an imaging-detected mass lesion without
providing estimates of its size would seem to rock our very
foundations. The universal criteria for assessment of tumour
response in preclinical trials are based solely on lesion num-
bers and sizes [1]. Staging and treatment of childhood neo-
plasms may depend on size measurements from diagnostic
images: the size of the primary and the size and number of
lung nodules. But is the ruler a useful tool? Are measurements
reproducible, accurate and meaningful? Or, in a few more
words: if both of us measure the same tumour, will we report
reasonably similar sizes? When I estimate tumour volumes, is
it reasonable to assume that most of my estimates are a
negligible distance away from the true volumes? Last, does
tumour size represent independent additional information that
improves the care for the individual child? The three questions
are logically connected. It may be possible to perfectly repro-
duce measurements that are far from a true volume, and it is
conceivable that we can have both reproducible and accurate
estimates that do not help to optimally stratify the child’s
clinical care. Conversely, evidence that tumour volume really
is useful for guiding therapy is negligible if we cannot produce
reliable and accurate estimates. Hence, we are forced to in-
vestigate the evidence in this order: reliability, accuracy,
clinical meaning.
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Attention to data that are not proved to be relevant can
introduce noise. In the worst case this noise confuses the
clinical decision-making process. For example, a child is
diagnosed with a kidney tumour. Chest CT shows three lung
nodules, all less than 5 mm in diameter, and the nodules are
not seen on the plain radiograph. The important question is
this: Does the child have metastatic disease? In the absence of
imaging criteria for lung nodules, the answer may be left to the
treatment team’s discretion. Is it perceivable that the team’s
decision is different if the primary tumour is very large and
causes major anatomical distortion compared to if the tumour
is small? Not impossible. But there is no evidence that the
volume of the primary tumour at diagnosis is related to the
likelihood of metastatic disease, nor that it is an independent
prognostic factor. Hence, the attention to size represents noise
that may bias the treatment decision.
This article is not a criticism of any particular individual or
group. As part of an initiative to raise awareness of the
importance of developing a strong evidence base for paediat-
ric radiology, the objectives are to question ingrained practices
(here, measuring tumours as a spinal reflex) and to promote
the role of a theoretical framework as a facilitator for rational
empirically based improvements. This article does not com-
prehensively review the field of paediatric oncological radiol-
ogy. Instead, it presents examples that illustrate some impor-
tant points.
Size of the primary tumour
Two tumour groups illustrate some problems concerning ra-
diologic measurements of primary tumours.
The Euro-E.W.I.N.G. (European Ewing tumour working
initiative of national groups) EE 99 protocol (most recent
version, 14 Sept 2010, not in the public domain) uses tumour
volume (CT or MRI, not further specified; three dimensions
with a spherical or cylindrical formula, not further specified)
for allocation of children to randomisation groups. Of interest
here, a child with localised disease and tumour ≥200 ml may
be randomised to receiving high-dose therapy (busulfan–mel-
phalan). The rationale is most likely found in the second
German sarcoma study (inclusion 1986–1991, 152 patient
data sets analysed), which reported a relative risk of about 2
for relapse in children with primary tumour ≥200 ml [2].
Children with primary tumour ≥100 ml had received intensi-
fied treatment in this study. Other works, however, did not
provide clear justification for a size criterion. For example,
Paulussen et al. [3] did not find evidence that size (volume
more or less than 100 ml) was an independent prognostic
factor (event-free survival or relapse rate) in children with
primary lung metastases. A larger study of patients diagnosed
1978–1993 did show a negative prognostic effect of tumour
volume ≥100 ml in both localised and metastatic disease [4].
Yet, the magnitude of this effect was not reported, volume data
were only available in 454/796 patients and tumour volumes
had been estimated from radiographs or CT images. The
volume data used to devise the stratification system therefore
seem to be somewhat deficient in rigour. In this context it is
also interesting to note that no radiologist is listed as contrib-
utor to the Euro-E.W.I.N.G. protocol.
The staging system for non-metastatic rhabdomyosarcoma
as proposed by the EpSSG (European paediatric soft-tissue
sarcoma group) RMS-2005 protocol (most recent version, 10
Jan 2013, not in the public domain) is complicated, with eight
defined subgroups. Imaging has a key role in the stratifica-
tions. For example, tumour maximum diameter must be ≤5 cm
(conforming to the cutoff between T1 and T2 in the tumor-
nodes-metastases [TNM] system) to be in the low-risk group
or in subgroup D of the standard-risk group. The same cutoff
is used for stratifications in synovial sarcoma and adult-type
sarcomas, but these will not be discussed here. One immediate
question: what does the protocol mean by “maximum dimen-
sion”? It is not a protocol requirement that volumetric acqui-
sitions be made and datasets reconstructed to seek the maxi-
mum diameter. Because only axial, coronal and sagittal mea-
surements are required, then tumour orientation could, in
effect, influence the staging, which intuitively seems inappro-
priate. A study of intermediate-risk patients with rhabdomyo-
sarcoma suggested that volume estimates are better than di-
ameters for risk stratification [5]. In particular, a cutoff at
20 ml optimised the stratification. This is the volume of a
spherical tumour with diameter 3.4 cm, which is well below
the cutoff diameter (5 cm) in the EpSSG 2005 protocol.
Observation of a change in size of tumour, for example
over the initial courses of chemotherapy, may seem to be a
biologically rational marker. Although re-staging on response
in size is not formalised, one could speculate that treatment
teams do consider this information informally. Intuitively one
would think that tumour growth or shrinkage during chemo-
therapy would be a marker of response. However, exceptions
have been documented, for example in nephroblastoma,
where tumour growth may be associated with differentiation
(intermediate risk by the International Society for Paediatric
Oncology [SIOP] renal tumour study criteria) and shrinkage
with residual blastemal predominance (high-risk by SIOP
criteria) [6]. This illustrates that macroscopic behaviour is
not necessarily associated with histopathological behaviour.
Again, formal evidence is required, even for what seems
obvious.
Lymph nodes
The absence of regional lymph node metastases is one crite-
rion discriminating standard risk from high risk in rhabdo-
myosarcoma. Biopsy is recommended if there is clinical/
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radiologic uncertainty. There is, however, no imaging recom-
mendation, except a preference for MRI. This matters because
some pulse sequences are relatively more sensitive for lymph
node metastases, e.g., diffusion-weighted imaging in adult
cancer [7]. CT-PET is optional only, but would perhaps be a
good candidate in a disease with relatively high rates (at least
15%) of nodal involvement [8], the presence of which dra-
matically influences the child’s prognosis. The alternative is to
let size criteria define which lymph nodes most likely contain
tumour deposits. There are two obvious problems involved.
First, there are no agreed upper limits for normal lymph node
dimensions by age group and anatomical region. Second,
early metastatic states are always missed by size criteria. The
latter problem is elaborated in the discussion of lung nodules
in nephroblastoma.
Unreliable numbers
Reliability means consistently good quality and performance.
In the field of radiology we may specify this as consistently
good quality of image acquisitions, consistent image repre-
sentation of identical structures or processes (regardless of site
and time) and precise interpretation within and between
readers. Surprisingly few published papers investigate the
reliability of radiologic findings. One may speculate that this
category of articles is perceived, by authors and editors alike,
to carry little prestige. Satisfactory reliability guarantees that
images are of adequate quality (e.g., that they sufficiently and
consistently discriminate neoplastic and non-neoplastic tissue)
and demonstrates that readers can be trained to repeatedly and
concertedly report (closely) consistent findings from the same
image set.
Intra- and inter-observer variabilities are perhaps the two
most comprehensive parameters for reliability, albeit they do
not necessarily measure differences among imaging devices.
Several statistics have been used to assess such variability, but
only variability of scalar measurements shall be considered
here. It is all too easy to find examples of various correlation
statistics being employed for this purpose. There are (at least)
three problems with this: (1) when two measurements are
performed of the same structure, these measurements are
destined to correlate. Anything else would come as a huge
surprise. (2) Correlation statistics tell us very little about the
degree of discrepancy, which clinically is the most important
piece of information. (3) Correlation statistics do not specify
any bias, for example whether the volumes of large tumours
are less precisely estimated compared to small ones. One
method that does convey all this relevant information is the
one proposed by Bland and Altman [9]. Here the difference
between paired measurements is plotted against the average of
the same pair. This produces a visually informative scatterplot.
Additionally, intervals (e.g., the ±2 standard deviation
interval) of the differences provide information about expect-
ed variability, the mean of the measurement errors show any
systematic bias, and a least-squares line reveals the potential
non-random influence of the magnitude of measurements on
errors.
As expected, there are few reports on reliability of tumour
measurements. Those in existence are mostly discouraging.
For example, at CT primary renal tumours measured indepen-
dently by two experienced radiologists had a variability of
±500 ml [6]. Although most of this was contributed by the
largest tumours, there was considerable variability among
medium-size tumours, e.g., around the cut-off size for high-
risk Ewing sarcoma (200 ml). A study of lung metastases in
adults demonstrated a ±20% difference in volume estimates
resulting from two CT scans performed with the same ma-
chine on the same day [10].
Studies of reliability should be the spine of radiologic
research. It seems obvious that reproducibly of results across
imaging devises, readers and time is a fundamental prerequi-
site for any test that aspires to offer clinical efficacy. The
radiologic society at large may perceive that certain observa-
tions are bound to be reliable. However, as we have seen, even
the humble measurement of tumour diameter is not. It follows,
therefore, that size measurements, among several other imag-
ing attributes, may not be suitable as discriminators until
image acquisition and interpretation have been standardised
and this standardisation has been proved to promote sufficient
reliability. It is paradoxical, therefore, that size is nonetheless
used as an independent staging parameter, e.g., in sarcoma, as
seen above. Several undesirable possibilities may be con-
ceived. For example, a tumour very close to the cut-off size
(e.g., 5 cm in rhabdomyosarcoma and 200 ml in Ewing
sarcoma)may be deliberatelymeasured generously if the child
clinically is thought to be in a high-risk group, or more
conservatively if the disease is thought to be low-risk. Under
this scheme the measurement in question has succumbed as an
independent characteristic and is no longer of value to the
patient. Poor reliability invites such practice, because “well,
this measurement is not very reproducible anyway.” As a
further consequence, when computing its prognostic validity
at study-level, the measurement is confounded by other risk
factors and is hence impossible to appraise as an independent
variable. This is a thought (but not impossible) scenario where
a hypothetically useful observation is rendered useless by
poor reproducibility.
The message is twofold. First, a radiologic test (observa-
tion, measurement) is not a candidate for further investigation
until it is scientifically plausible that it is reliable. This requires
standardisation across imaging devises and among readers. It
also calls for dissemination of results, for which researchers
and editors are equally responsible. It must be expected from
radiology representatives on oncological study groups that
they consider reliability a fundamental requirement before
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implementing imaging measurements as part of any staging
system. Absolute cut-off points require particularly high pre-
cision. Second, if imaging findings are to be part of a staging
system then image acquisition and interpretation need to be
clearly defined. Quality control needs to be implemented. This
may be in the form of central review that (1) may help align
the quality of imaging among participating centres and (2)
may decrease the variability in reported quantities.
What makes a lung nodule a metastasis?
Increasing sensitivity coupled with stationary specificity is
recognised as a problem in the diagnosis of lung metastases
[11]. In particular, false-positive results may cause upstaging.
If benign (e.g., inflammatory) lung nodules are frequent in
children with neoplastic disease, then this may be a real
problem. Silva et al. [12] found lung nodules in 111/488
(23%) children with neoplastic disease at CT at diagnosis.
There was probably little selection bias in this study, so the
proportion seems high. Further, out of 26 biopsied nodules, 17
(65%) were benign. It therefore seems that a nodule, per se, is
not necessarily a metastatic deposit, even in a child with
cancer. Size criteria for discrimination of metastases and be-
nign nodules have been proposed, so a discussion of lung
nodules is apt in our context.
Lung metastases in rhabdomyosarcoma are defined as ei-
ther at least one lung nodule ≥10 mm, or two or more well-
defined nodules 5–10 mm, or 5 or more well-defined nodules
<5 mm. The European Ewing protocol defines metastatic lung
disease as at least one pulmonary/pleural nodule >10 mm, or
more than one nodule >5 mm. Accurate diagnosis of metasta-
tic disease is important because it may warrant high-dose
chemotherapy. Interestingly, Paulussen et al. [3] found that
in Ewing sarcoma the number of pulmonary metastases was
not a prognostic factor whereas children with unilateral lung
metastases were more likely to survive. Might this surprising
finding have arisen from suboptimal diagnosis of lung metas-
tases, i.e. false interpretation of nodules as metastases? This
provocative interpretation may be supported by the finding
that patients with metastases to lungs only do better than those
with bone or bone marrowmetastases [13]. It may be apposite
to ask: what makes a nodule a metastasis?
In the SIOP 2001 renal tumour study, about 4% of all
children with nephroblastoma had lung nodules seen on CT
but not on chest radiograph. About two-thirds of these were
treated as if they had metastatic disease. But compared with
the one-third treated less intensively, there was no difference
in survival [14]. One may interpret this as suggesting that
small nodules are unlikely to represent metastases, hence that
nodule size is a candidate criterion for discriminating benign
and malignant lung nodules. Alternatively, small lung metas-
tasis may resolve with non-metastatic treatment. There are
several problems with this interpretation, however. First, chest
CT was optional under the SIOP 2001 protocol, so the chil-
dren who did have chest CT might represent a select group.
Perhaps they weremore likely to have some other risk factors?
If so, the presence of lung nodules, whether malignant or
benign, might have been less important overall. Second, the
children with CT-only lung nodules were not randomised to
receiving treatment for localised or metastatic disease. Hence,
factors other than the CT findings most likely confounded the
results. Finally, the CT-only criterion is a poor substitute for
actual measurements. It must be less reliable by the fact that it
is more difficult radiographically to detect a paraspinal nod-
ule, say, than a nodule of the same size in the lateral mid-zone.
A similarly constructed study based on the National Wilms
Tumor studies 4 and 5 demonstrated improved 5-year event-
free survival among children with CT-only lung lesions who
received additional chemotherapy [15]. However, the overall
survival among these children was, as in the SIOP study, no
different from survival among those treated for a local stage.
The slight difference between these two studies probably only
illustrates how difficult it is to gain accurate knowledge retro-
spectively from studies not originally incorporating good im-
aging questions. Too much bias is introduced by discretionary
CT-scanning (selection bias), lack of clear staging criteria
(information bias, because other data were allowed to influ-
ence care decisions) and non-randomisation (treatment bias).
We have seen that large clinical studies do not support a
size criterion for lung nodules in nephroblastoma. Further,
relatively large imaging studies specifically designed to inves-
tigate discrimination of benign and malignant lung nodules
did not find nodule size to be of significant value [12, 16]. On
the contrary, at primary staging in children with extra-
pulmonary malignant disease, Silva et al. [12] found higher
proportions of benign lesions both among nodules of diameter
5 mm or less and among nodules of diameter 10 mm and
more. Hence, the available literature seems to contradict the
notion that size (or other popular features like number, shape
and border, for that matter) is a useful discriminator.
Theoretically, nodule size may be a candidate discriminator
only if metastatic nodules are small (i.e. less than a set crite-
rion) for a relatively short period of their lifetime. But because
tumour growth is exponential, this seems unlikely. For exam-
ple, let a spherical lung metastasis have a doubling time of
20 days, which seems reasonable [17]. When its diameter is
1 mm the volume is about 0.52 mm3, and at 10 mm the
volume is about 520 mm3. Hence the volume has increased
1,000-fold. With the assumed doubling time, this would take
about 200 days (20×log 1,000/log 2). For comparison, an
increase from 10 mm (4,200 mm3) to 20 mm (33,500 mm3;
8-fold increase in volume) would only take about 60 days
(20×log 8/log 2). From these results we see that if there are
lung nodules, then there is a non-negligible probability that
they will be small at diagnosis. This may be contrary to
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common belief and certainly challenges the approach of sev-
eral protocol guidelines. There is, however, one potential
theoretical justification for the current approach. If benign
lung nodules at the time of staging are even more likely to
be small, then a high-pass threshold on size would improve
our specificity, albeit at the cost of lower sensitivity. Unfortu-
nately, knowledge about this is very difficult to obtain because
biopsy proof is not routinely obtained. Not knowing the
likelihood of distribution by size for benign versus malignant
nodules makes it impossible to construct a receiver operating
characteristics curve and hence impossible to obtain knowl-
edge about the predictive values of observed nodules based on
size. The size criteria given in several treatment protocols,
therefore, seem arbitrary at best and illogical in the worst case.
It may be argued that the burden of lung nodules in itself may
have predictive validity; however, as discussed above, out-
come results from clinical trials are too confounded to allow
proofs for this.
Seeking a fitting face of validity
In comparing a test result (e.g., a measurement) with a refer-
ence standard, we assess the test’s validity. Validity, in the
widest sense, can be defined as the quality of being logically
or factually sound. For example, let us define an attribute:
image-based estimates of tumour size. It may perhaps be
proved plausible that the attribute is indeed very close to the
actual measured sizes of excised lesions. If so, our chosen
attribute has the quality of being factually sound. By definition
it logically follows that it is valid.
However, this broad definition of validity does not consider
clinical utility and may therefore lead us off-target. Our pri-
mary task is not to predict which size of specimen-pot needs to
be available in the operating theatre. Rather, we aim at guiding
the clinical care for the child. In oncological care this means to
help in assigning (and, if needed, re-assigning) the patient to
an optimal combination and sequence of therapeutic agents
and modalities. Such staging (and re-staging), as performed in
accordance with a set of rules, often contains imaging criteria,
as illustrated above. What about the validity of the staging
formula? Is it factually sound? Although it was straightfor-
ward to assess the face validity of a size estimate, we are now
in deep water. We seek a trait against which we can evaluate
the performance of staging, but what could this be? Certainly
not tumour size, dissemination, genetic makeup, etc., because
these attributes are themselves criteria that define the staging
formula. In other words, the staging system is a construct of
(all) currently available pieces of information. Hence it cannot
be validated by assessing its strength of association with
concurrent observables (concurrent validity). Similarly, the
staging system can hardly be validated prospectively (predic-
tive validity) because stage itself is fundamental to treatment
allocation. Staging systems evolve by cumulatively incorpo-
rating qualities and quantities that are thought to represent
(independent) prognostic factors. It is the breadth and com-
prehensiveness of these data, and the logical plausibility of the
staging formula, that justify staging systems and may give
them content validity.
It follows that using an established staging system as a
reference standard for a (new) radiologic test is problematic in
several ways. (1) The staging system is only a construct— it is
not an observable of nature. Using it as a reference standard,
we can only assess our test’s construct validity. A close
association between the test and this reference standard, there-
fore, does not bring us closer to understanding a biological
process— it only tells us whether we have a test that emulates
a human-made scoring system. There is a benefit only if the
new test is more reproducible or has lower costs (in the wider
sense: cheaper, earlier, less-invasive) compared to the refer-
ence. (2) Few people set out to find a test that is not associated
with a reference standard. Perhaps non-correlation is per-
ceived as scientific failure? However, if we seek attributes
with potential to add new dimensions to existing staging (or
other scoring) systems, then non-association is exactly what
we should go looking for. For example, amplification of the
MYCN gene in neuroblastic tumours is not associated with the
clinico–radiologic disease stage. If it were, it would have been
history. But because it does not co-vary with stage, still being
a predictive factor, it is an appealing quality and indeed useful
as an additional dimension for stratifying treatment of neuro-
blastoma. As another example, one may find that change in
standard uptake values at PET-CT is closely associated with
histopathological response scoring in osteosarcoma. But so
long as we continue to perform histopathological specimen
examination (we will), this result in itself is of no particular
benefit to the patient.
These few paragraphs illustrate that a reference standard
and formal validity testing, per se, do not guarantee an effec-
tive measurement. The hope lies in its degree of dissociation
from existing constructs and in its predictive power.
A step in the right direction
The International Neuroblastoma Risk Group Staging System
[18, 19] with related imaging guidelines [20] exemplifies a
rational, size-ignorant stratification strategy. Rather than ab-
solute size and extent, the local-regional staging is based on
anatomical relations that chiefly define the likelihood (at
initial diagnosis) that the primary tumour can be completely
excised, a principle also used for staging of hepatoblastoma
[21]. To concentrate the radiologic workup on the local be-
haviour of tumour appears to be rational because non-
metastatic and metastatic disease are more accurately separat-
ed by other modalities (e.g., metaiodobenzylguanidine
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scintigraphy, histopathological examination of bone marrow
samples). The more limited role for radiology is
complemented by independent well-defined and proven risk
factors (age, MYCN oncogene amplitude, chromosome 11q
status, DNA ploidy, tumour histology and differentiation).
The result is a multi-dimensional staging system that, at least
theoretically, is preferable. The main weaknesses are perhaps
that the image-defined risk factors are only based on consen-
sus and that central review of imaging is not in operation.
Summary of findings
This informal investigation has highlighted a few problems.
(1) Oncological treatment protocols call for radiologic as-
sessment of tumour size but may nevertheless fail to
specify image acquisition and measurement techniques.
(2) The perfect measurement does not exist, so reporting
measurements without error estimates is meaningless.
Yet we know very little about how measurements vary
depending on tumour shape and location, imaging device
and reader. If oncological staging systems use absolute
cut-offs for size, then the magnitude of measurement
variability around a cut-off point will determine the
proportion of patients who are (falsely) assigned a higher
or lower stage purely because of (random) measurement
error.
(3) Although tumour burden is ultimately linked to the mor-
tality of neoplastic disease, we have little knowledge
about the prognostic value of tumour volume at the time
of diagnosis.
(4) If clinical prognosis is a function of tumour size, then it
must be assumed to be a continuous function. But size-
dependent staging systems treat size as if it were discrete.
Because size is not accurately and precisely estimated by
imaging, staging of tumours close to the cut-off points is
less predictable. Also, if measurements are consequently
biased by other factors, including clinical, this may con-
found the interpretation of imaging data from clinical
trials.
(5) The size of lung nodules is used in staging systems,
implying that size is a discriminator between benign
and malignant lesions. Still, lack of knowledge about
the sensitivity and specificity precludes any prediction
of the clinical value of such assessments.
The way forward
Revision of staging criteria may be difficult because oncolog-
ical trials are pragmatic and cumulative. They are pragmatic
because the staging systems are devised to have predictive
(and not necessarily concurrent pathological) validity. For
example, it may not be required that a lung nodule actually
represents a metastasis if, for the cohort of patients, lung
nodules are associated with poorer prognosis. Oncological
trials are cumulative because new prognostic factors are added
without the replacement of existing ones. Like with a house of
cards, replacing a card in the middle is difficult. Reshuffling
an entire floor is impossible. Nevertheless, oncological care is
moving towards ever more refined stratification to improve
survival and minimise adverse effects of treatments, and im-
aging will no doubt be a partner in this project. One funda-
mental requirement for a successful partnership is active con-
tributions from radiologists during the development of treat-
ment protocols. These inputs fall into two main categories.
First, there is a duty to explore new imaging qualities or
quantities that may have prognostic value. If these turn out to
mimic the existing staging system, they are of little value to
development. The focus needs to be on validating prognostic
factors that are independent of existing ones. Similarly, re-
validation of existing measurements (e.g., primary tumour,
lung nodules) is required to make staging more rational. As
seen in neuroblastoma, accurate diagnosis of metastatic dis-
ease is crucial to more rational local staging. The addition of
multimodal imaging, including nuclear medicine, is a prom-
ising route.
Second, but just as important, there is an urgent need for
standardisation of imaging acquisition and interpretation.
Measurement errors must be estimated and acknowledged,
and absolute cut-off points (whether for size or other scalars)
should only be used in conjunction with other criteria (e.g.,
metabolic imaging) unless the quantity in question can be
obtained with sufficient precision.
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